Low risk of the TMPRSS2 inhibitor camostat mesylate and its metabolite GBPA to act as perpetrators of drug-drug interactions

A Present Update of Camostate and the Role in SARS-CoV-2 Infection

“…The involvement of researchers from Hannover, Germany, made it possible to analyze the antiviral effect of Camostate in real lung tissue as well [6]. Camostate and GBPA inhibit SARS-CoV-2 infection of lung tissue [15]. The camostate mesilate-containing drug Foipan® has been available on the Japanese market since 1986 .…”

“…Camostate inhibits in vitro various pancreatic and plasmatic proteolytic enzymes such as trypsin, plasmin, pancreatic kallikrein, plasma kallikrein, and thrombin, as well as the hydrolytic activity of C1r and C1 esterase [33,36]. Camostate further inhibits the cellular protease TMPRSS2 in vitro [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][20][21][22][23][24][25][26][27][28][29][31][32]34,35]. The efficacy of Camostate in different cell cultures has already been demonstrated .…”

“…Camostates inhibits TMPRSS2, the enzyme is expressed on the human cell surface after autocatalytic activation, mainly in the small intestine and to a lesser extent in the liver, heart, prostate, thymus and lung . As per the analysis, SARS-CoV-2, virus responsible for the COVID-19, requires TMPRSS2 exists in human body to get inside the host cell, which may provide target for the treatment [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][20][21][22][23][24][25][26][27][28][29]31,32,34,35]. Therapeutic efficacy in COVID-19 patients remains to be tested in clinical trials [2][3][4]6,24,32].…”